Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.00
Bid: 1,604.00
Ask: 1,604.50
Change: -14.00 (-0.87%)
Spread: 0.50 (0.031%)
Open: 1,608.00
High: 1,615.00
Low: 1,602.50
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TREASURIES-Yields lower, curve flatter ahead of Fed

Fri, 11th Dec 2020 21:23

(New throughout)
By Kate Duguid
NEW YORK, Dec 11 (Reuters) - A risk-off move drove Treasury
yields down across maturities on Friday, with the two-year yield
falling to a four-month low, furthering speculation that the
Federal Reserve may announce adjustments to its Treasury
purchases at next week's meeting.
The fall in yields was partly attributable to reports that
congressional wrangling over a spending package and coronavirus
aid could drag on through Christmas. Also pulling yields lower
was news that European pharmaceutical companies Sanofi SA
and GlaxoSmithKline Plc would delay the launch
of their COVID-19 vaccine until late next year, a setback in the
global fight against the pandemic.
Those macroeconomic drivers explain the fall in the
benchmark 10-year yield and the 30-year bond yield
to their lowest since Dec. 1. In afternoon trade,
both had pulled back from those lows, with the 10-year last down
1.5 basis points at 0.892% and the 30-year down 1.4 basis points
at 1.622%.
The move in the two-year yield to its lowest
since Aug. 7, however, was surprising, as the yield has been
roughly anchored since the Fed moved interest rates to zero at
the beginning of the pandemic. It was last down 2 basis points
at 0.119%.
Analysts argued the two-year move was likely not purely the
result of macroeconomic drivers. Yields on Treasury bills - debt
with a maturity of one year or less - are all less than 10 basis
points away from 0%, according to Tradeweb data.
"The idea that bills could potentially go to zero is taking
twos, threes and fives along with it," said Justin Lederer,
Treasury analyst and trader at Cantor Fitzgerald.
Since the lows hit in March, the 10-year yield has risen
more than 60 basis points, and the 30-year has risen nearly 100.
The two-year yield, by comparison, was just a basis point and a
half higher than the all-time low it hit in May.
Both long rates have increased enough in the past several
months that some analysts believe the Fed will purchase more
longer-dated debt to cap yields and keep borrowing costs low.
Since March the Fed has bought more than $2 trillion worth of
Treasury debt, most of it in shorter-dated notes.
If the Fed were to lengthen the average maturity of its
Treasury holdings - by purchasing the same amount but buying
more longer-dated debt and less shorter-dated debt - it could
also have the effect of bolstering Treasury bills and
shorter-dated notes away from zero.
"I can see the Fed trying to do something to alleviate that.
They definitely don't want bills trading negative, or repo
trading negative," said Lederer.

December 11 Friday 4:14PM New York / 2114 GMT
Price Current Net
Yield % Change
(bps)
Three-month bills 0.0725 0.0735 -0.006
Six-month bills 0.0825 0.0837 0.000
Two-year note 100-3/256 0.119 -0.020
Three-year note 99-216/256 0.1772 -0.019
Five-year note 100-16/256 0.3623 -0.021
Seven-year note 100 0.625 -0.021
10-year note 99-212/256 0.8931 -0.015
20-year bond 99-76/256 1.4156 -0.016
30-year bond 100-12/256 1.623 -0.013

DOLLAR SWAP SPREADS
Last (bps) Net
Change
(bps)
U.S. 2-year dollar swap 7.50 0.25
spread
U.S. 3-year dollar swap 6.00 0.00
spread
U.S. 5-year dollar swap 5.50 0.00
spread
U.S. 10-year dollar swap -1.00 -0.50
spread
U.S. 30-year dollar swap -29.00 -1.00
spread


(Reporting by Kate Duguid; Editing by Ken Ferris and Jonathan
Oatis)

More News
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.